Abstract #1772

Sun Y, Albert M, Wong K, Al-Hashem R, Ji H

Epidermal growth factor receptor (EGFRvIII) mutations results in non-small cell lung cancer (NSCLC). In this study we evaluated the efficacy of Traceva on EGFRvIII induced lung tumors in a NSCLC mouse model. A total of 8 NSCLC mice were evaluated, 4 mice with tumor greater than 100mL were treated with Traceva. The NSCLC responded to Traceva dramatically with an average result of 64% reduction in tumor volume within the first 7 days and 90% reduction within 14 days of daily oral treatment. The decrease in tumor volume for these subjects followed an exponential decrease with a regression value of 0.9979.